CD107a (LAMP-1), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD107a (LAMP-1), Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD107a (LAMP-1), Human |
| Clone | REAL565 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | allophycocyanin (APC) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD107a (LAMP-1) Antibody, anti-human, APC, REAdye_lease™. Clone REAL565 is an antibody fragment derived from the full CD107a antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL565 recognizes the CD107a antigen, also known as lysosome-associated membrane protein 1 (LAMP-1), a 110-140 kDa type I membrane glycoprotein. It is a widely expressed intracellular protein, located in the lysosomal/endosomal membrane. CD107a transiently located on the plasma membrane can be used as a marker for CD8+ T cell degranulation following stimulation. It is also expressed to a lower extent on activated NK cells. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
| Immunogen | n/a |
| Other Names | LAMP-1, LAMPA, LGP120, LAMP1 |
| Gene, Accession # | n/a |
| Catalog # | 130-124-360 |
| Price | $490 |
| Order / More Info | CD107a (LAMP-1), Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Mane, S. M. et al. (1989) Purification and characterization of human lysosomal membrane glycoproteins. Arch Biochem Biophys. 268 (1): 360-378. | Betts, M. R. et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281: 65-78. | Wang, Q. et al. (2017) LAMP1 expression is associated with poor prognosis in breast cancer. Oncol Lett 14 (4): 4729-4735. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies